Background Although 23-valent polysaccharide pneumococcal vaccine (PPV) does not
prevent community-acquired pneumonia (CAP), it might still improve outcomes in those who …

Background. There is debate surrounding the effectiveness of the 23-valent pneumococcal
polysaccharide vaccine (PPV). We determined whether PPV was associated with reduced …

Background. Vaccination with pneumococcal polysaccharide reduces the incidence of
bacteremic pneumococcal disease in adults. We investigated the impact of prior …

Background It is vigorously debated whether pneumococcal polysaccharide vaccination
(PPV) reduces risk of acute coronary syndrome (ACS) events in patients with community …

The aim of this study was to evaluate the effect of prior pneumococcal vaccination on the
clinical outcome of 554 consecutive hospitalized adults with community-acquired …

Background. The benefits of using the 23-valent pneumococcal polysaccharide vaccine
(PPV23) are controversial. This study assessed clinical effectiveness of PPV23 in preventing …

Background Streptococcus pneumoniae is the chief cause of pneumonia in older adults, but
it remains unclear whether use of the pneumococcal polysaccharide vaccine alters the …

Background The effectiveness of the 23-valent pneumococcal polysaccharide vaccine
(PPV23) to prevent hospitalizations due to Streptococcus pneumoniae community-acquired …

Objectives The 23-valent pneumococcal polysaccharide vaccine (PPV) is recommended for
prevention of pneumococcal diseases in adults at risk. Few data exist on time-, age-and sex …

Background: Because of the prevalence of pneumococcal pneumonia, the substantial
morbidity and mortality associated with many pneumococcal infections, and an increase in …